Skip to main content
Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.040
+0.320 (11.76%)
At close: Mar 9, 2026, 4:00 PM EDT
3.040
0.00 (0.00%)
After-hours: Mar 9, 2026, 5:20 PM EDT

Esperion Therapeutics Revenue

Esperion Therapeutics had revenue of $87.31M in the quarter ending September 30, 2025, with 69.10% growth. This brings the company's revenue in the last twelve months to $303.80M, up 2.83% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.

Revenue (ttm)
$303.80M
Revenue Growth
+2.83%
P/S Ratio
2.22
Revenue / Employee
$999,349
Employees
304
Market Cap
715.71M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024332.31M215.98M185.66%
Dec 31, 2023116.33M40.86M54.14%
Dec 31, 202275.48M-2.97M-3.79%
Dec 31, 202178.45M-149.10M-65.52%
Dec 31, 2020227.55M79.18M53.37%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Tilray Brands 837.32M
Emergent BioSolutions 742.90M
Pacira BioSciences 726.41M
Amphastar Pharmaceuticals 719.89M
Ironwood Pharmaceuticals 296.15M
Kamada 174.79M
SIGA Technologies 172.25M
Cronos Group 146.59M
Revenue Rankings

ESPR News

More News